新辅助放化疗治疗食管癌的磁共振早期退缩指数(ERI)作为疗效预测因子:前瞻性ESCAPE试验的中期分析
前瞻性ESCAPE试验纳入2020年1月至2023年5月30例食管癌患者,行PET-MRI评估新辅助放化疗前后及放疗中的肿瘤退缩。25例可分析患者中10例达完全缓解(pCR+ cCR),ERImid预测完全缓解的AUC为0.78(p=0.014),联合ERImid与Vpre的模型AUC达0.93(p<0.0001)。作者认为ERI可能为完全缓解的潜在预测因子,但样本量有限,需更大样本验证。
要点
- ERImid预测食管癌新辅助放化疗后完全缓解的AUC为0.78(p=0.014)。
- ERImid联合Vpre的两变量逻辑模型AUC提升至0.93(p<0.0001)。
- 轮廓勾画者间变异未影响结果。
核心结论
- 尽管样本量有限,ESCAPE试验中期分析提示ERI可能作为食管癌新辅助放化疗后完全缓解的潜在预测因子。
- 作者认为需要在更大规模人群上进一步验证。
研究设计与样本
- 前瞻性ESCAPE试验,2020年1月至2023年5月纳入30例食管癌患者。
- 新辅助放化疗方案为41.4 Gy/23次,同步卡铂和紫杉醇。
- 于新辅助放化疗前(tpre)、放疗中(tmid)及新辅助放化疗后术前2-6周(tpost)行PET-MRI。
- 由两名观察者在T2w MRI上勾画GTV体积(Vpre、Vmid、Vpost),检验ERI及其他体积退缩参数对pCR+cCR的预测价值。
主要发现
- 分析时25例患者数据完整,其中3/25例影像学完全缓解者拒绝手术,2/3例为cCR。
- 共10/25例患者达pCR+cCR(pCR=8/22)。
- ERImid和ERIpost均能区分pCR+cCR患者,ERImid表现更优(AUC 0.78,p=0.014)。
- ERImid联合Vpre的两变量逻辑模型表现提升(AUC 0.93,p<0.0001)。
- GTV勾画的观察者间变异未影响结果。
关键数值与推荐
- 完全缓解定义为pCR或cCR;拒绝手术者若18个月后无局部复发则评估为cCR。
- ERImid预测pCR+cCR的AUC为0.78(p=0.014)。
- ERImid联合Vpre模型预测pCR+cCR的AUC为0.93(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文述样本量有限(Despite the limited numbers)。
- 作者认为需在更大规模人群上进一步验证(Further validation on larger populations is warranted)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The early regression index (ERI) predicts treatment response in rectal cancer patients. Aim of current study was to prospectively assess tumor response to neoadjuvant chemo-radiotherapy (nCRT) of locally advanced esophageal cancer using ERI, based on MRI. MATERIAL AND METHODS: From January 2020 to May 2023, 30 patients with esophageal cancer were enrolled in a prospective study (ESCAPE). PET-MRI was performed: i) before nCRT (tpre); ii) at mid-radiotherapy, tmid; iii) after nCRT, 2-6 weeks before surgery (tpost); nCRT delivered 41.4 Gy/23fr with concurrent carboplatin and paclitaxel. For patients that skipped surgery, complete clinical response (cCR) was assessed if patients showed no local relapse after 18 months; patients with pathological complete response (pCR) or with cCR were considered as complete responders (pCR + cCR). GTV volumes were delineated by two observers (Vpre, Vmid, Vpost) on T2w MRI: ERI and other volume regression parameters at tmid and tpost were tested as predictors of pCR + cCR. RESULTS: Complete data of 25 patients were available at the time of the analysis: 3/25 with complete response at imaging refused surgery and 2/3 were cCR; in total, 10/25 patients showed pCR + cCR (pCR = 8/22). Both ERImid and ERIpost classified pCR + cCR patients, with ERImid showing better performance (AUC:0.78, p = 0.014): A two-variable logistic model combining ERImid and Vpre improved performances (AUC:0.93, p < 0.0001). Inter-observer variability in contouring GTV did not affect the results. CONCLUSIONS: Despite the limited numbers, interim analysis of ESCAPE study suggests ERI as a potential predictor of complete response after nCRT for esophageal cancer. Further validation on larger populations is warranted.
引用
- Fiorino C, Palumbo D, Mori M, et al. Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial. Radiother Oncol. 2024. PMID: 38369025. doi:10.1016/j.radonc.2024.110160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。